Theranautilus, an innovative deep-tech company specializing in nanorobotic solutions, has raised $1.2 million in seed funding. This funding round was led by Pi Ventures with support from Golden Sparrow Ventures and notable angel investors like Abhishek Goyal, Founder of Tracxn, and Lalit Keshre, CEO of Grow.
The funding will help Theranautilus become the first company in the world to commercialize nanorobotics-based medical devices, starting with dental care. The company also plans to use these funds to refine its go-to-market strategy and expand its technology to other healthcare applications.
Targeting Dental Care Innovations
Theranautilus is initially focusing on dental care, addressing challenges like dental hypersensitivity, which affects over 2 billion people globally and represents a $6 billion market. Unlike conventional toothpaste-based treatments, Theranautilus offers a groundbreaking solution. Its precision nanorobots target specific areas within dental tissues, delivering biocompatible materials that repair damage.
This 10-minute procedure provides long-lasting relief and has been tested extensively on animals. Human trials for this technology are set to begin in 2025, marking a significant step forward in healthcare innovation.
Expanding Beyond Dental Applications
Theranautilus has ambitious plans to expand its nanorobotic solutions beyond dental care. Backed by international patents and advanced technology, the company aims to develop theranostics-based interventions for managing cancer therapy and other diseases.
Founded in 2020, Theranautilus was incubated at the Indian Institute of Science (IISc) by Professor Ambarish Ghosh, Debayan Dasgupta, and Shanmukh Srinivas. This team brings years of expertise across diverse fields, driving the company’s mission to develop targeted therapeutic technologies.
Vision for a Healthcare Revolution
Speaking about the funding, Theranautilus Co-founder Shanmukh Srinivas said: “Our nanorobotic technology addresses health challenges at a microscopic level with exceptional precision. This funding allows us to introduce a new paradigm in healthcare, starting with dental care and expanding into revolutionary treatments for critical diseases.”
Theranautilus’s journey signifies a major leap in medical innovation, aiming to transform healthcare with cutting-edge nanorobotic solutions.
